// App-Quantinova.ai

Su1412 : Is There a Higher Rate of Infliximab Dose Optimization in Initial Responders Between UC and CD Cases?

Researchers

Presenter

  • Joanne M. Stempak

Principal Investigators

  • Mark S. Silverberg

Medical Centers

  • Dept of Gastroenterology, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

  • Crohn's disease

Biomarkers

  • C reactive protein

  • Human albumin

  • Tumor necrosis factor

Drug/Treatment

  • Infliximab

Outcome

  • N/A

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved